Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014186291 - NOVEL VACCINE COMPOSITIONS COMPRISING IMMUNOSTIMULATORY OLIGONUCLEOTIDES

Publication Number WO/2014/186291
Publication Date 20.11.2014
International Application No. PCT/US2014/037705
International Filing Date 12.05.2014
IPC
A61K 39/39 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 39/008 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
002Protozoa antigens
008Leishmania antigens
A61K 39/27 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
27Equine rhinopneumonitis virus
CPC
A61K 2039/55561
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55561CpG containing adjuvants; Oligonucleotide containing adjuvants
A61K 2039/55566
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55566Emulsions, e.g. Freund's adjuvant, MF59
A61K 2039/55577
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55577Saponins; Quil A; QS21; ISCOMS
A61K 39/008
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
002Protozoa antigens
008Leishmania antigens
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/27
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
27Equine rhinopneumonitis virus
Applicants
  • ZOETIS SERVICES LLC [US]/[US]
Inventors
  • DOMINOWSKI, Paul, Joseph
  • RAI, Sharath, K.
  • SLY, Laurel, Mary
  • COOK, Corey, Patrick
  • MWANGI, Duncan
  • FOSS, Dennis, L.
  • KREBS, Richard, Lee
Agents
  • VASILYEV, Vyacheslav
Priority Data
61/823,18914.05.2013US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL VACCINE COMPOSITIONS COMPRISING IMMUNOSTIMULATORY OLIGONUCLEOTIDES
(FR) NOUVELLES COMPOSITIONS DE VACCIN COMPRENANT DES OLIGONUCLÉOTIDES IMMUNOSTIMULATEURS
Abstract
(EN) The invention provides a vaccine composition comprising an antigen component and an adjuvant component, wherein the adjuvant component comprises a P-class immunostimulatory oligonucleotide and either a combination of a saponin and a sterol; or an oily phase comprising an oil and, optionally, one or more emulsifiers, said oily phase comprising 2-20% v/v of the vaccine composition, wherein said antigen component is an EHV antigen or a Leishmania antigen.
(FR) La présente invention concerne une composition de vaccin comprenant une composante antigène et une composante adjuvant, la composant adjuvant comprenant un oligonucléotide immunostimulateur de classe P et soit une association de saponine et d'un stérol; soit une phase huileuse comprenant une huile et, facultativement, un ou plusieurs émulsifiants, ladite phase huileuse constituant 2 à 20 % v/v de la composition de vaccin, ladite composante antigène étant un antigène EHV ou un antigène Leishmania.
Latest bibliographic data on file with the International Bureau